The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen in the Omicron variant of concern and its sublineages, demanding the development of Omicron Spike-based vaccines. Herein, we review the evidence in animal models and topline results from ongoing clinical trials with such updated vaccines, discussing the pros and cons for their deployment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692555 | PMC |
| http://dx.doi.org/10.3390/v14112488 | DOI Listing |
Publication Analysis
Top Keywords
omicron spike-based
8
spike-based vaccines
8
spike-based updated
4
updated covid-19
4
covid-19 vaccines?
4
vaccines? evidence
4
evidence pipeline
4
pipeline wild-type
4
wild-type sars-cov-2
4
sars-cov-2 spike-based
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!